Exemptions in FDA regulations for clinical studies seeking to establish bioavailability or bioequivalence of generic drugs should be closed so the agency can respond to problems uncovered in clinical research inspections, according to a report from the Government Accountability Office (GAO) that notes FDA has pushed back a proposed rulemaking on the issue several times.